PIPELINES

TheraVectys’ mission is to provide solutions for oncological and infectious disease indications through therapeutic, prophylactic as well as personalized vaccination. TheraVectys supports its development through international academic and industrial collaborations with European and Chinese partners.

Among the pre-clinical studies and proofs of concept studies conducted by the Pasteur Institute-TheraVectys Joint-Laboratory, TheraVectys has selected 19 major indications for pre-clinical and clinical developments for the coming years.

It illustrates the potential of its vaccine platform in oncology and infectious diseases, which is based both upon the very promising results obtained by existing proof of concept animal studies, and the market interests materialized by collaboration agreements signed with major partners in 2017 and 2018.

TheraVectys’ strong ambition to be recognized as a leading therapeutic oncological platform is supported by recent proof of concept results. In the foreseeable future, TheraVectys intends to directly or via collaboration prepare or launch clinical trials.

TheraVectys has already started a Phase IIa clinical trial on HPV-induced cancers (cervix and oropharyngeal cancer).

THV01 is our lentiviral vector-based therapeutic vaccine candidate being developed for HIV-1 infection, It has completed a Phase I/II randomized, double-blind, placebo-controlled clinical trial in Europe and we are planning to submit an application to EMA to initiate a global Phase II/III clinical trial.

In parallel, the development of our vaccine candidate targeting HBV chronic infection is expected to adopt a staged design, beginning with an early-phase clinical study and progressing toward Phase II/III trials contingent on favorable clinical outcomes.